 c. Myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis fulfilling the criteria listed below: i. Intermediate-2 or high risk disease according to the Dynamic International Prognostic Scoring System DIPSS classification ii. refractory or intolerant to JAK inhibitor therapy, or deemed - ineligible for ruxolitinib therapy due to pre- existing cytopenias thrombocytopenia 50,000uL, anemia hemoglobin 9gdL or red cell transfusion dependence.Requiring further therapy based on the presence of one or more cytopenias Hb 10 gdL andor red cell transfusion dependence, platelets 50,000μL, or ANC 1,000μL, excess blasts 5 in the peripheral blood or bone marrow, or palpable splenomegaly 